Antibody Information
General Information of This Antibody (ID: ANTI0APGIB)
| Antibody Name | Anti N256-glycosylated CEACAM5 and CEACAM6 antibody |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | CEACAM5; CEACAM6 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
EBC-129 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: age ≥18/21 years (US/Singapore); weight 40-120kg; advanced/metastatic solid tumors refractory to standard therapy; ECOG PS ≤2 (Part A) or 0-1 (Parts B-D); adequate hepatic/renal/bone marrow function per protocol.
|
||||
| Administration Dosage |
EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and Day 1 of each 21- or 28-Day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05701527 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1A/B Study to Evaluate the Safety and Tolerability of EBC-129 As a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumours
|
||||
| Primary Endpoint |
Primary endpoints include SAE/TEAE incidence (pre-screening to EOS), MTD/RP2D determination (Parts A/B/D), and ORR assessment (Parts C/D per RECIST v1.1) over 2 years.
|
||||
| Other Endpoint |
Secondary endpoints comprise efficacy measures (DCR, DoR, TTP, PFS, OS), PK parameters (Cmax, Ctrough, AUC, Tmax, t1/2 for EBC-129/pembrolizumab), immunogenicity (ADA/neutralizing antibodies), and tumor response comparisons (Part A) evaluated over 3.3 years.
|
||||